Latest Safety News

Page 9 of 252
Westgold Resources delivered record FY26 production, earnings and cash generation while expanding its gold reserves and laying out a path towards 500,000 ounces a year. The challenge now shifts from funding growth to executing a crowded pipeline of mine, mill and exploration projects without losing operational discipline.
Maxwell Dee
Maxwell Dee
23 Oct 2026
Anatara Lifesciences narrowed its FY2026 loss and ended the year with A$470,917 in cash, but warned that further capital raising is included in its business plan and may be necessary to remain a going concern. Its AOC anti-obesity candidate produced statistically significant results in mice, while mechanism-of-action data remained inconclusive and development was placed on hold.
Victor Sage
Victor Sage
23 Oct 2026
AML3D has carried $16.8 million of orders into FY27, with its US defence expansion driving a sales pipeline above $80 million. Customer receipts rose 19% in the September quarter, while the company retained $24.42 million in cash to fund capacity expansion.
Victor Sage
Victor Sage
23 Oct 2026
Bass Oil’s September-quarter production rose 21% to 23,944 barrels after Bunian 6 came online, while sales revenue reached A$2.82 million. Cash fell to A$2.07 million as drilling and development spending continued, leaving the company with an estimated two quarters of funding under its Appendix 5B calculation.
Victor Sage
Victor Sage
23 Oct 2026
Arovella has released two clinical batches of its off-the-shelf CAR-iNKT therapy, activated two trial sites and begun screening patients ahead of expected first dosing in October. The biotech ended September with A$11.6 million in cash, rising to about A$15.63 million pro forma after an R&D rebate.
Ada Torres
Ada Torres
23 Oct 2026
Argent BioPharma ended the September quarter with just A$11,000 in cash after A$734,000 of operating outflows, despite retaining A$7.4 million of unused convertible financing capacity. The company is simultaneously expanding its commercial portfolio through NLC antiviral rights and a CannEpil veterinary programme.
Victor Sage
Victor Sage
23 Oct 2026
Amplia Therapeutics has received an A$4.78 million refundable R&D tax rebate, giving the clinical-stage biotechnology company additional cash to advance its FAK inhibitor programs. The funds will support multiple narmafotinib trials and related research, including studies involving Lilly.
Victor Sage
Victor Sage
22 Oct 2026
MLG Oz delivered a stronger earnings year, with statutory NPAT rising 19.2% and underlying EBITDA margin expanding to 13.4%. The mining services group has resumed dividends while taking on higher fleet investment and debt ahead of FY2027.
Victor Sage
Victor Sage
22 Oct 2026
Starpharma has submitted its European trial application for DEP HER2-Lu and completed manufacture of clinical material, bringing its lead radiopharmaceutical closer to first patient dosing. The biotech also took control of Petalion, collected a Radiopharm option fee and finished the quarter with AUD $34.4 million in cash.
Ada Torres
Ada Torres
22 Oct 2026
Racura Oncology says both Phase 1 RC220 programs have cleared their opening dose cohorts without dose-limiting toxicities, while its Korean expansion broadens the CPACS trial. The company ended September with $30.7 million in cash, which management says funds committed activities into mid-2028.
Victor Sage
Victor Sage
22 Oct 2026
Recce Pharmaceuticals has granted Arrotex exclusive rights to commercialise its investigational RECCE 327 topical gel in Australia and New Zealand. The agreement offers a potential profit-share stream, but no upfront payments, sales forecast or approval have been disclosed.
Ada Torres
Ada Torres
22 Oct 2026
ABx Group says manufacture of the major equipment for its ALCORE hydrogen fluoride pilot plant is substantially complete, while electrical and civil works continue at Bell Bay in Tasmania. EPA Tasmania has accepted the project’s Environmental Effects Report for final assessment, but planning approval and commissioning remain ahead.
Victor Sage
Victor Sage
22 Oct 2026

Browse the archive

Full archive